Metabolomics markers in Neurology: current knowledge and future perspectives for therapeutic targeting

References

• Zapalska-Sozoniuk M, Chrobak L, Kowalczyk K, et al. Is it useful to use several “omics” for obtaining valuable results? Mol Biol Rep. 2019 Jun;46(3):3597–3606.
   PubMed Web of Science ®Google Scholar
• Hassan-Smith G, Wallace GR, Douglas MR, et al. The role of metabolomics in neurological disease. J Neuroimmunol. 2012;248(1–2):48‐52.
   PubMed Web of Science ®Google Scholar
• Friedland RP, Budinger TF, Ganz E, et al. Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F] fluorodeoxyglucose. J Comput Assist Tomogr. 1983;7(4):590–598.
   PubMed Web of Science ®Google Scholar
• Foster NL, Chase TN, Mansi L, et al. Cortical abnormalities in Alzheimer’s disease. Ann Neurol. 1984;16(6):649–654.
   PubMed Web of Science ®Google Scholar
• Minoshima S, Giordani B, Berent S, et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol. 1997;42(1):85–94.
   PubMed Web of Science ®Google Scholar
• Sakamoto S, Ishii K, Sasaki M, et al. Differences in cerebral metabolic impairment between early and late onset types of Alzheimer’s disease. J Neurol Sci. 2002;200(1–2):27–32.
   PubMed Web of Science ®Google Scholar
• Ishii K, Sasaki H, Kono AK, et al. Comparison of gray matter and metabolic reduction in mild Alzheimer’s disease using FDG-PET and voxel-based morphometric MR studies. Eur J Nucl Med Mol Imaging. 2005;32(8):959–963.
   PubMed Web of Science ®Google Scholar
• Panov A, Schonfeld P, Dikalov S, et al. The neuromediator glutamate, through specific substrate interactions, enhances mitochondrial ATP production and reactive oxygen species generation in nonsynaptic brain mitochondria. J Biol Chem. 2009;21(284):14448–14456.
   Google Scholar
• Panov AV, Kubalik N, Zinchenko N, et al. Metabolic and functional differences between brain and spinal cord mitochondria underlie different predisposition to pathology. Am J Physiol Regul Integr Comp Physiol. 2011;4(300):844–854.
   Google Scholar
• Trushina E, Mielke MM. Recent advances in the application of metabolomics to Alzheimer’s disease. Biochim Biophys Acta. 2014;1842(8):1232–1239.
   PubMed Web of Science ®Google Scholar
• Han J, Kaufman RJ. The role of ER stress in lipid metabolism and lipotoxicity. J Lipid Res. 2016 Aug;57(8):1329–1338.
   PubMed Web of Science ®Google Scholar
• Yi L, Liu W, Wang Z, et al. Characterizing Alzheimer’s disease through metabolomics and investigating anti-Alzheimer’s disease effects of natural products. Ann N Y Acad Sci. 2017 Jun;1398(1):130–141.
   PubMed Web of Science ®Google Scholar
• Ebert D, Haller RG, Walton ME. Energy contribution of octanoate to intact rat brain metabolism measured by13C nuclear magnetic resonance spectroscopy. J Neurosci. 2003 Jul 2;23(13):5928–5935.
   PubMed Web of Science ®Google Scholar
• Weed LH, Cushing H. Studies on cerebrospinal fluid. VIII. The effect of pituitary extract upon its secretion (choroidorrhoea). Amer J Physiol. 1915;36(2):77–103.
   Google Scholar
• Weed LH. The cerebrospinal fluid. Physiol Rev. 1922;2(2):171–203.
   Google Scholar
• Cushing H. Studies in lntracranial physiology and surgery. London: Oxford Univ. Press; 1926. p. 146.
   Google Scholar
• Kasser TR, Deutch A, Martin RJ. Uptake and utilization of metabolites in specific brain sites relative to feeding status. Physiol Behav. 1986;36(6):1161–1165.
   PubMed Web of Science ®Google Scholar
• el-Bacha RS, Minn A. Drug metabolizing enzymes in cerebrovascular endothelial cells afford a metabolic protection to the brain. Cell Mol Biol (Noisy-le-grand). 1999 Feb;45(1):15–23.
   PubMed Web of Science ®Google Scholar
• Greene DA, Winegrad AI. In vitro studies of the substrates for energy production and the effects of insulin on glucose utilization in the neural components of peripheral nerve. Diabetes. 1979;28(10):878–887.
   PubMed Web of Science ®Google Scholar
• Véga C, Martiel JL, Drouhault D, et al. Uptake of locally applied deoxyglucose, glucose and lactate by axons and Schwann cells of rat vagus nerve. J Physiol. 2003;546(2):551–564.
   PubMed Web of Science ®Google Scholar
• Ludvigson MA, Sorenson RL. Immunohistochemical localization of aldose reductase. I. Enzyme purification and antibody preparation–localization in peripheral nerve, artery, and testis. Diabetes. 1980;29(6):438–449.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Calcutt NA, Ramos KM, et al. Novel sites of aldose reductase immunolocalization in normal and streptozotocin-diabetic rats [published correction appears in j peripher nerv syst 2007;12:64]. J Peripher Nerv Syst. 2006;11(4):274–285.
   PubMed Web of Science ®Google Scholar
• Cortese A, Zhu Y, Rebelo AP, et al. Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes. Nat Genet. 2020;52(5):473‐481.
   Web of Science ®Google Scholar
• Freeman OJ, Unwin RD, Dowsey AW, et al. Metabolic dysfunction is restricted to the sciatic nerve in experimental diabetic neuropathy. Diabetes. 2016 Jan;65(1):228–238.
   PubMed Web of Science ®Google Scholar
• Fink BR, Cairns AM. A bioenergetic basis for peripheral nerve fiber dissociation. Pain. 1982 Apr;12(4):307–317.
   PubMed Web of Science ®Google Scholar
• Low PA, Schmelzer JD, Ward KK, et al. Experimental chronic hypoxic neuropathy: relevance to diabetic neuropathy. Am J Physiol. 1986 Jan;250(1 Pt 1):E94–9.
   PubMed Web of Science ®Google Scholar
• Low PA, Schmelzer JD, Ward KK. The effect of age on energy metabolism and resistance to ischaemic conduction failure in rat peripheral nerve. J Physiol. 1986 May;374(1):263–271.
   PubMedGoogle Scholar
• Zala D, Hinckelmann MV, Yu H, et al. Vesicular glycolysis provides on-board energy for fast axonal transport. Cell. 2013;152(3):479‐491.
   PubMed Web of Science ®Google Scholar
• Skene DJ, Arendt J. Human circadian rhythms: physiological and therapeutic relevance of light and melatonin. Ann Clin Biochem. 2006 Sep;43(Pt 5):344–353.
   PubMedGoogle Scholar
• Damiola F, Le Minh N, Preitner N, et al. Restricted feeding uncouples circadian oscillators in peripheral tissues from the central pacemaker in the suprachiasmatic nucleus. Genes Dev. 2000 Dec 1;14(23):2950–2961.
   PubMed Web of Science ®Google Scholar
• Stokkan KA, Yamazaki S, Tei H, et al. Entrainment of the circadian clock in the liver by feeding. Science. 2001 Jan 19;291(5503):490–493.
   PubMed Web of Science ®Google Scholar
• Oster H, Challet E, Ott V, et al. The functional and clinical significance of the 24-hour rhythm of circulating glucocorticoids. Endocr Rev. 2017 Feb 1;38(1):3–45.
   PubMed Web of Science ®Google Scholar
• Zani F, Breasson L, Becattini B, et al. PER2 promotes glucose storage to liver glycogen during feeding and acute fasting by inducing Gys2 PTG and G L expression. Mol Metab. 2013;2(3):292–305.
   PubMed Web of Science ®Google Scholar
• Kornmann B, Schaad O, Bujard H, et al. System-driven and oscillator-dependent circadian transcription in mice with a conditionally active liver clock. PLoS Biol. 2007;5(2):e34.
   PubMed Web of Science ®Google Scholar
• Lamia KA, Storch KF, Weitz CJ. Physiological significance of a peripheral tissue circadian clock. Proc Natl Acad Sci USA.. 2008;105(39):15172–15177.
   PubMed Web of Science ®Google Scholar
• Davies SK, Ang JE, Revell VL, et al. Effect of sleep deprivation on the human metabolome. Proc Natl Acad Sci USA. 2014;111(29):10761–10766.
   PubMed Web of Science ®Google Scholar
• Honma A, Revell VL, Gunn PJ, et al. Effect of acute total sleep deprivation on plasma melatonin, cortisol and metabolite rhythms in females. Eur J Neurosci. 2020 Jan; 51(1):366–378.
   PubMed Web of Science ®Google Scholar
• Dallmann R, Viola AU, Tarokh L, et al. The human circadian metabolome. Proc Natl Acad Sci USA. 2012;109:2625–2629.
   PubMed Web of Science ®Google Scholar
• Kasukawa T, Sugimoto M, Hida A, et al. Human blood metabolite timetable indicates internal body time. Proc Natl Acad Sci USA. 2012;109(37):15036–15041.
   PubMed Web of Science ®Google Scholar
• Chua EC, Shui G, Lee IT, et al. Extensive diversity in circadian regulation of plasma lipids and evidence for different circadian metabolic phenotypes in humans. Proc Natl Acad Sci USA. 2013;110(35):14468–14473.
   PubMed Web of Science ®Google Scholar
• Wishart DS, Tzur D, Knox C, et al. HMDB: the human metabolome database. Nucleic Acids Res. 2007;35(Database):521–526.
   Google Scholar
• Wishart DS, Knox C, Guo AC, et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res. 2009;37(783):603–610.
   Google Scholar
• Weljie AM, Newton J, Mercier P, et al. Targeted profiling: quantitative analysis of 1H NMR metabolomics data. Anal Chem. 2006;78(13):4430–4442.
   PubMed Web of Science ®Google Scholar
• Surowiec I, Karimpour M, Gouveia-Figueira S, et al. Multi-platform metabolomics assays for human lung lavage fluids in an air pollution exposure study. Anal Bioanal Chem. 2016;408(17):4751–4764.
   PubMed Web of Science ®Google Scholar
• Contrepois K, Jiang L, Snyder M. Optimized analytical procedures for the untargeted metabolomic profiling of human urine and plasma by combining hydrophilic interaction (HILIC) and reverse-phase liquid chromatography (RPLC)–mass spectrometry. Mol Cell Proteomics. 2015;14(6):1684–1695.
   PubMed Web of Science ®Google Scholar
• Chen S, Kong H, Lu X, et al. Pseudotargeted metabolomics method and its application in serum biomarker discovery for hepatocellular carcinoma based on ultra high-performance liquid chromatography/triple quadrupole mass spectrometry. Anal Chem. 2013;85(17):8326–8333.
   PubMed Web of Science ®Google Scholar
• Khamis MM, Adamko DJ, El-Aneed A. Mass spectrometric based approaches in urine metabolomics and biomarker discovery. Mass Spectrom Rev. 2017;36(2):115–134.
   PubMed Web of Science ®Google Scholar
• Matsuo T, Tsugawa H, Miyagawa H, et al. Integrated strategy for unknown EI-MS identification using quality control calibration curve. multivariate analysis. EI-MS spectral database, and retention index prediction. Anal Chem. 2017;89(12):6766–6773.
   PubMed Web of Science ®Google Scholar
• Dossin E, Martin E, Diana P, et al. Prediction models of retention indices for increased confidence in structural elucidation during complex matrix analysis: application to gas chromatography coupled with high-resolution mass spectrometry. Anal Chem. 2016;88(15):7539–7547.
   PubMed Web of Science ®Google Scholar
• Ni Y, Su M, Qiu Y, et al. ADAP-GC 3.0: improved peak detection and deconvolution of co-eluting metabolites from GC/TOF-MS data for metabolomics studies. Anal Chem. 2016;88(17):8802–8811.
   PubMed Web of Science ®Google Scholar
• Domingo-Almenara X, Brezmes J, Vinaixa M, et al. eRah: A Computational Tool Integrating Spectral Deconvolution and Alignment with Quantification and Identification of Metabolites in GC/MS-Based Metabolomics. Anal Chem. 2016;88(19):9821–9829.
   PubMed Web of Science ®Google Scholar
• Shao Y, Ye G, Ren S, et al. Metabolomics and transcriptomics profiles reveal the dysregulation of the tricarboxylic acid cycle and related mechanisms in prostate cancer. Int J Cancer. 2018 Jul 15;143(2):396–407.
   PubMed Web of Science ®Google Scholar
• Ye G, Liu Y, Yin P, et al. Study of induction chemotherapy efficacy in oral squamous cell carcinoma using pseudotargeted metabolomics. J Proteome Res. 2014;13(4):829 1994–2004.
   Web of Science ®Google Scholar
• Zhou Y, Song R, Zhang Z, et al. The development of plasma pseudotargeted GC-MS metabolic profiling and its application in bladder cancer. Anal Bioanal Chem. 2016 Sep;408(24):6741–6749.
   PubMed Web of Science ®Google Scholar
• Zhou J, Yin Y. Strategies for large-scale targeted metabolomics quantification by liquid chromatography-mass spectrometry. Analyst. 2016;141(23):6362–6373.
   PubMed Web of Science ®Google Scholar
• Chen J, Wang W, Lv S, et al. Metabonomics study of liver cancer based on ultra performance liquid chromatography coupled to mass spectrometry with HILIC and RPLC separations. Anal Chim Acta. 2009;650(1):3–9.
   PubMed Web of Science ®Google Scholar
• Ren S, Shao Y, Zhao X, et al. Integration of metabolomics and transcriptomics reveals major metabolic pathways and potential biomarker involved in prostate cancer. Mol Cell Proteomics. 2016;15(1):154–163.
   PubMed Web of Science ®Google Scholar
• Luo P, Yin P, Hua R, et al. A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma. Hepatology. 2018;67(2):662–675.
   PubMed Web of Science ®Google Scholar
• Zhou L, Wang Q, Yin P, et al. Serum metabolomics reveals the deregulation of fatty acids metabolism in hepatocellular carcinoma and chronic liver diseases. Anal Bioanal Chem. 2012;926(1):203–213.
   Google Scholar
• Son J, Lyssiotis CA, Ying H, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 2013;496(7443):101–105.
   PubMed Web of Science ®Google Scholar
• Cieslarova Z, Lopes FS, Do Lago CL, et al. Capillary electrophoresis tandem mass spectrometry determination of glutamic acid and homocysteine’s metabolites: potential biomarkers of amyotrophic lateral sclerosis. Talanta. 2017;170:63–68.
   PubMed Web of Science ®Google Scholar
• Rodrigues KT, Mekahli D, Tavares MF, et al. Development and validation of a CE-MS method for the targeted assessment of amino acids in urine. Electrophoresis. 2016;37(7–8):1039–1047.
   PubMed Web of Science ®Google Scholar
• Ciborowski M, Adamska E, Rusak M, et al. CE-MS-based serum fingerprinting to track evolution of type 2 diabetes mellitus. Electrophoresis. 2015 Sep;36(18):2286–2293.
   PubMed Web of Science ®Google Scholar
• Hirayama A, Kami K, Sugimoto M, et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 2009;69(11):4918–4925.
   PubMed Web of Science ®Google Scholar
• Bojstrup M, Petersen BO, Beeren SR, et al. Fast and accurate quantitation of glucans in complex mixtures by optimized heteronuclear NMR spectroscopy. Anal Chem. 2013;85(18):8802–8808.
   PubMed Web of Science ®Google Scholar
• Nagana Gowda GA, Raftery D. Whole blood metabolomics by 1H NMR spectroscopy provides a new opportunity to evaluate coenzymes and antioxidants. Anal Chem. 2017;89(8):4620–4627.
   PubMed Web of Science ®Google Scholar
• Winter G, Kroemer JO. Fluxomics - connecting ‘omics analysis and phenotypes. Environ Microbiol. 2013;15(7):1901–1916.
   PubMed Web of Science ®Google Scholar
• Srour O, Young JD, Eldar YC. Fluxomers: a new approach for C-13 metabolic flux analysis. BMC Syst Biol. 2011 Aug 16;5(1):129.
   PubMedGoogle Scholar
• Nöh K, Droste P, Wiechert W. Visual workflows for 13 C-metabolic flux analysis. Bioinformatics. 2015;31(3):346–354.
   PubMed Web of Science ®Google Scholar
• Aguilar E, Marin de Mas I, Zodda E, et al. Metabolic reprogramming and dependencies associated with epithelial cancer stem cells independent of the epithelial-mesenchymal transition program. Stem Cells. 2016 May;34(5):1163–1176.
   PubMed Web of Science ®Google Scholar
• Ahn E, Kumar P, Mukha D, et al. Temporal fluxomics reveals oscillations in TCA cycle flux throughout the mammalian cell cycle. Mol Syst Biol. 2017 Nov 6;13(11):953.
   PubMed Web of Science ®Google Scholar
• Rhee EP, Gerszten RE. Metabolomics and cardiovascular biomarker discovery. Clin Chem. 2012;58(1):139–147.
   PubMed Web of Science ®Google Scholar
• Wilson RB, Hoggard JC, Synovec RE. Fast, high peak capacity separations in gas chromatography-time-of-flight mass spectrometry. Anal Chem. 2012;84(9):4167‐4173.
   Web of Science ®Google Scholar
• Gathungu RM, Kautz R, Kristal BS, et al. The integration of LC-MS and NMR for the analysis of low molecular weight trace analytes in complex matrices. Mass Spectrom Rev. 2020;39(1–2):35‐54.
   PubMed Web of Science ®Google Scholar
• Yin P, Peter A, Franken H, et al. Preanalytical aspects and sample quality assessment in metabolomics studies of human blood. Clin Chem. 2013;59(5):833‐845.
   PubMed Web of Science ®Google Scholar
• Stevens VL, Hoover E, Wang Y, et al. Pre-analytical factors that affect metabolite stability in human urine, plasma, and serum: a review. Metabolites. 2019;9(8):156.
   PubMed Web of Science ®Google Scholar
• Kim K, Mall C, Taylor SL, et al. Mealtime, temporal, and daily variability of the human urinary and plasma metabolomes in a tightly controlled environment. PLoS One. 2014 Jan 24;9(1):e86223.
   PubMed Web of Science ®Google Scholar
• Houtkooper RH, Argmann C, Houten SM, et al. The metabolic footprint of aging in mice. Sci Rep. 2011;1(1):134.
   PubMedGoogle Scholar
• Son N, Hur HJ, Sung MJ, et al. Liquid chromatography-mass spectrometry-based metabolomic analysis of livers from aged rats. J Proteome Res. 2012;11(4):2551–2558.
   PubMed Web of Science ®Google Scholar
• Calvani R, Brasili E, Praticò G, et al. Fecal and urinary NMR-based metabolomics unveil an aging signature in mice. Exp Gerontol. 2014;49:5–11.
   PubMed Web of Science ®Google Scholar
• Ivanisevic J, Stauch KL, Petrascheck M, et al. Metabolic drift in the aging brain. Aging (Albany NY). 2016;8(5):1000–1020.
   PubMedGoogle Scholar
• Kregel KC, Zhang HJ. An integrated view of oxidative stress in aging: basic mechanisms, functional effects, and pathological considerations. Am J Physiol Regul Integr Comp Physiol. 2007;292(1):18–36.
   PubMed Web of Science ®Google Scholar
• Findeisen HM, Pearson KJ, Gizard F, et al. Oxidative stress accumulates in adipose tissue during aging and inhibits adipogenesis. PLoS ONE. 2011;6(4):e18532.
   PubMed Web of Science ®Google Scholar
• Lee SH, Park S, Kim H, et al. Metabolomic approaches to the normal aging process. Metabolomics. 2014;10(6):1268–1292.
   Web of Science ®Google Scholar
• Yu Z, Zhai G, Singmann P, et al. Human serum metabolic profiles are age dependent. Aging Cell. 2012 Dec;11(6):960–967.
   PubMed Web of Science ®Google Scholar
• Chung HY, Cesari M, Anton S, et al. Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Res Rev. 2009;8(1):18–30.
   PubMed Web of Science ®Google Scholar
• Hong SE, Heo HS, Kim DH, et al. Revealing system-level correlations between aging and calorie restriction using a mouse transcriptome. Age (Omaha). 2010;32(1):15–30.
   Google Scholar
• Choe M, Jackson C, Yu BP. Lipid peroxidation contributes to age-related membrane rigidity. Free Radic Biol Med. 1995 Jun;18(6):977–984.
   PubMed Web of Science ®Google Scholar
• Wick G, Grubeck-Loebenstein B. The aging immune system: primary and secondary alterations of immune reactivity in the elderly. Exp Gerontol. 1997 Jul-Oct;32(4–5):401–413.
   PubMed Web of Science ®Google Scholar
• Mittelstrass K, Ried JS, Yu Z, et al. Discovery of sexual dimorphisms in metabolic and genetic biomarkers. PLoS Genet. 2011;7(8):e1002215.
   PubMed Web of Science ®Google Scholar
• Menni C, Kastenmüller G, Petersen AK, et al. Metabolomic markers reveal novel pathways of ageing and early development in human populations. Int J Epidemiol. 2013;42(4):1111–1119.
   PubMed Web of Science ®Google Scholar
• Krumsiek J, Mittelstrass K, Do KT, et al. Gender‐specific pathway differences in the human serum metabolome. Metabolomics. 2015;11(6):1815–1833.
   PubMed Web of Science ®Google Scholar
• Dunn WB, Lin W, Broadhurst D, et al. Molecular phenotyping of a UK population: defining the human serum metabolome. Metabolomics. 2015;11(1):9–26.
   PubMed Web of Science ®Google Scholar
• Chaleckis R, Murakami I, Takada J, et al. Individual variability in human blood metabolites identifies age‐related differences. Proc Natl Acad Sci USA. 2016;113(16):4252–4259.
   PubMed Web of Science ®Google Scholar
• Rist MJ, Roth A, Frommherz L, et al. Metabolite patterns predicting sex and age in participants of the Karlsruhe Metabolomics and Nutrition (KarMeN) study. PLoS One. 2017;12(8):e0183228.
   PubMed Web of Science ®Google Scholar
• Darst BF, Koscik RL, Hogan KJ, et al. Longitudinal plasma metabolomics of aging and sex. Aging (Albany NY). 2019 Feb 24;11(4):1262–1282.
   PubMedGoogle Scholar
• Gonzalez‐Covarrubias V, Beekman M, Uh HW, et al. Lipidomics of familial longevity. Aging Cell. 2013;12(3):426–434.
   PubMed Web of Science ®Google Scholar
• Vermeulen A. Andropause. Maturitas. 2000 Jan 15;34(1):5–15.
   PubMed Web of Science ®Google Scholar
• Auro K, Joensuu A, Fischer K, et al. A metabolic view on menopause and ageing. Nat Commun. 2014;5(1):4708.
   PubMedGoogle Scholar
• Ke C, Hou Y, Zhang H, et al. Plasma metabolic profiles in women are menopause dependent. PLoS One. 2015;10(11):e0141743.
   PubMed Web of Science ®Google Scholar
• Jové M, Maté I, Naudí A, et al. Human aging is a metabolome-related matter of gender. J Gerontol A Biol Sci Med Sci. 2016;71(5):578‐585.
   PubMed Web of Science ®Google Scholar
• Jové M, Naudí A, Gambini J, et al. A stress-resistant lipidomic signature confers extreme longevity to humans. J Gerontol A Biol Sci Med Sci. 2017;72(1):30‐37.
   PubMed Web of Science ®Google Scholar
• Pradas I, Jové M, Huynh K, et al. Exceptional human longevity is associated with a specific plasma phenotype of ether lipids. Redox Biol. 2019;21:101127.
   PubMed Web of Science ®Google Scholar
• Yin H, Xu L, Porter NA. Free radical lipid peroxidation: mechanisms and analysis. Chem Rev. 2011;111(10):5944‐5972.
   Web of Science ®Google Scholar
• Przedborski S, Vila M, Jackson-Lewis V. Series Introduction: neurodegeneration: what is it and where are we? J Clin Invest. 2003 Jan;111(1):3–10.
   PubMed Web of Science ®Google Scholar
• Bjornevik K, Zhang Z, ÉJ O, et al. Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis. Neurology. 2019 Apr 30;92(18):e2089–e2100.
   PubMed Web of Science ®Google Scholar
• Palamiuc L, Schlagowski A, Ngo ST, et al. A metabolic switch toward lipid use in glycolytic muscle is an early pathologic event in a mouse model of amyotrophic lateral sclerosis. EMBO Mol Med. 2015;7(5):526–546.
   PubMed Web of Science ®Google Scholar
• Kumar A, Bala L, Kalita J, et al. Metabolomic analysis of serum by (1) H NMR spectroscopy in amyotrophic lateral sclerosis. Clin Chim Acta. 2010;411(7–8):563–567.
   PubMed Web of Science ®Google Scholar
• Schonfeld P, Reiser G. Why does brain metabolism not favor burning of fatty acids to provide energy? - Reflections on disadvantages of the use of free fatty acids as fuel for brain. J Cereb Blood Flow Metab. 2013;33(10):1493–1499.
   PubMed Web of Science ®Google Scholar
• Tracey TJ, Steyn FJ, Wolvetang EJ, et al. Neuronal lipid metabolism: multiple pathways driving functional outcomes in health and disease. Front Mol Neurosci. 2018;11:10.
   PubMed Web of Science ®Google Scholar
• Cacabelos D, Ayala V, Granado-Serrano AB, et al. Interplay between TDP-43 and docosahexaenoic acid-related processes in amyotrophic lateral sclerosis. Neurobiol Dis. 2016;88:148‐160.
   PubMed Web of Science ®Google Scholar
• Blasco H, Corcia P, Pradat PF, et al. Metabolomics in cerebrospinal fluid of patients with amyotrophic lateral sclerosis: an untargeted approach via high-resolution mass spectrometry. J Proteome Res. 2013;12(8):3746‐3754.
   PubMed Web of Science ®Google Scholar
• Wuolikainen A, Andersen PM, Moritz T, et al. ALS patients with mutations in the SOD1 gene have an unique metabolomic profile in the cerebrospinal fluid compared with ALS patients without mutations. Mol Genet Metab. 2012;105(3):472‐478.
   PubMed Web of Science ®Google Scholar
• Pean A, Steventon GB, Waring RH, et al. Pathways of cysteine metabolism in MND/ALS. J Neurol Sci. 1994;124:59–61.
   PubMed Web of Science ®Google Scholar
• Woolsey PB. Cysteine, sulfite, and glutamate toxicity: a cause of ALS? J Altern Complement Med. 2008;14(9):1159–1164.
   PubMed Web of Science ®Google Scholar
• Wuolikainen A, Moritz T, Marklund SL, et al. Disease related changes in the cerebrospinal fluid metabolome in amyotrophic lateral sclerosis detected by GC/TOFMS. PLoS One. 2011;6(4):17947.
   Web of Science ®Google Scholar
• Ginsberg L, Rafique S, Xuereb JH, et al. Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer’s disease brain. Brain Res. 1995;698(1–2):223–226.
   PubMed Web of Science ®Google Scholar
• Han X, Holtzman DM, McKeel DW Jr. Plasmalogen deficiency in early Alzheimer’s disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J Neurochem. 2001;77(4):1168–1180.
   PubMed Web of Science ®Google Scholar
• Han X. Lipid alterations in the earliest clinically recognizable stage of Alzheimer’s disease: implication of the role of lipids in the pathogenesis of Alzheimer’s disease. Curr Alzheimer Res. 2005;2(1):65–77.
   PubMedGoogle Scholar
• Goodenowe DB, Cook LL, Liu J, et al. Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer’s disease and dementia. J Lipid Res. 2007 Nov;48(11):2485–2498.
   PubMed Web of Science ®Google Scholar
• Wood PL, Mankidy R, Ritchie S, et al. Circulating plasmalogen levels and Alzheimer disease assessment scale-cognitive scores in Alzheimer patients. J Psychiatry Neurosci. 2010 Jan;35(1):59–62.
   PubMed Web of Science ®Google Scholar
• Brites P, Waterham H, Wanders R. Functions and biosynthesis of plasmalogens in health and disease. Biochim Biophys Acta. 2004;1636(2–3):219–231.
   PubMed Web of Science ®Google Scholar
• Oresic M, Hyotylainen T, Herukka SK, et al. Metabolome in progression to Alzheimer’s disease. Transl Psychiatry. 2011;1(12):e57.
   PubMedGoogle Scholar
• Xu XH, Huang Y, Wang G, et al. Metabolomics: a novel approach to identify potential diagnostic biomarkers and pathogenesis in Alzheimer’s disease. Neurosci Bull. 2012;28(5):641–648.
   PubMed Web of Science ®Google Scholar
• Han X, Rozen S, Boyle SH, et al. Metabolomics in early Alzheimer’s disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One. 2011;6(7):e21643.
   PubMed Web of Science ®Google Scholar
• Mielke MM, Bandaru VV, Haughey NJ, et al. Serum sphingomyelins and ceramides are early predictors of memory impairment. Neurobiol Aging. 2010;31(1):17–24.
   PubMed Web of Science ®Google Scholar
• Bernath MM, Bhattacharyya S, Nho K, et al. Serum triglycerides in Alzheimer disease: relation to neuroimaging and CSF biomarkers. Neurology. 2020;94(20):e2088‐e2098.
   PubMed Web of Science ®Google Scholar
• Toledo JB, Arnold M, Kastenmuller G, et al. Metabolic network failures in Alzheimer’s disease: a biochemical road map. Alzheimers Dement. 2017;13(9):965–984.
   PubMed Web of Science ®Google Scholar
• Tynkkynen J, Chouraki V, van der Lee SJ, et al. Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimer’s disease: a prospective study in eight cohorts. Alzheimers Dement. 2018;14(6):723–733.
   PubMed Web of Science ®Google Scholar
• Chouraki V, Preis SR, Yang Q, et al. Association of amine biomarkers with incident dementia and Alzheimer’s disease in the Framingham Study. Alzheimers Dement. 2017;13(12):1327–1336.
   PubMed Web of Science ®Google Scholar
• van der Lee SJ, Teunissen CE, Pool R, et al. Circulating metabolites and general cognitive ability and dementia: evidence from 11 cohort studies. Alzheimers Dement. 2018;14(6):707–722.
   PubMed Web of Science ®Google Scholar
• Ansoleaga B, Jové M, Schlüter A, et al. Deregulation of purine metabolism in Alzheimer’s disease. Neurobiol Aging. 2015;36(1):68‐80.
   PubMed Web of Science ®Google Scholar
• Niedzwiecki MM, Walker DI, Howell JC, et al. High-resolution metabolomic profiling of Alzheimer’s disease in plasma. Ann Clin Transl Neurol. 2020 Jan;7(1):36–45.
   PubMed Web of Science ®Google Scholar
• Graham SF, Holscher C, Green BD. Metabolic signatures of human Alzheimer’s disease (AD): 1H NMR analysis of the polar metabolome of post-mortem brain tissue. Metabolomics. 2014;10(4):744–753.
   Web of Science ®Google Scholar
• Kaddurah-Daouk R, Zhu H, Sharma S, et al. Alterations in metabolic pathways and networks in Alzheimer’s disease. Transl Psychiatry. 2013;3(4):e244.
   PubMedGoogle Scholar
• Kaddurah-Daouk R, Rozen S, Matson W, et al. Metabolomic changes in autopsy-confirmed Alzheimer’s disease. Alzheimers Dement. 2011;7(3):309–317.
   PubMed Web of Science ®Google Scholar
• Tukiainen T, Tynkkynen T, Meakinen V-P, et al. A multimetabolite analysis of serum by 1H NMR spectroscopy: early systemic signs of Alzheimer’s disease. Biochem Biophys Res Comm. 2008;375(3):356–361.
   PubMed Web of Science ®Google Scholar
• Czech C, Berndt P, Busch K, et al. Metabolite profiling of Alzheimer’s disease cerebrospinal fluid. PLoS One. 2012;7(2):e31501.
   PubMed Web of Science ®Google Scholar
• Motsinger-Reif AA, Zhu H, Kling MA, et al. Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer’s disease from normal cognitive aging. Acta Neuropathol Commun. 2013;1(1):28.
   PubMedGoogle Scholar
• Mittal R, Gupta RL. In vitro antioxidant activity of piperine. Methods Find Exp Clin Pharmacol. 2000;22(5):271–274.
   PubMedGoogle Scholar
• Mujumdar AM, Dhuley JN, Deshmukh VK, et al. Antiinflammatory activity of piperine. Jpn J Med Sci Biol. 1990;43(3):95–100.
   PubMedGoogle Scholar
• Murata K, Matsumura S, Yoshioka Y, et al. Screening of beta-secretase and acetylcholinesterase inhibitors from plant resources. J Nat Med. 2015;69(1):123–129.
   PubMed Web of Science ®Google Scholar
• Stoessel D, Stellmann JP, Willing A, et al. Metabolomic profiles for primary progressive multiple sclerosis stratification and disease course monitoring. Front Hum Neurosci. 2018;12:226.
   PubMed Web of Science ®Google Scholar
• Del Boccio P, Pieragostino D, Di Ioia M, et al. Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis. J Proteomics. 2011;74(12):2826–2836.
   PubMed Web of Science ®Google Scholar
• Mulder C, Wahlund LO, Teerlink T, et al. Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer’s disease. J Neural Transm. 2003;110(8):949–955.
   PubMed Web of Science ®Google Scholar
• Treede I, Braun A, Sparla R, et al. Anti-inflammatory effects of phosphatidylcholine. J Biol Chem. 2007;282(37):27155–27164.
   PubMed Web of Science ®Google Scholar
• Miller LG Jr, Young JA, Ray SK, et al. Sphingosine toxicity in EAE and MS: evidence for ceramide generation via serine-palmitoyltransferase activation. Neurochem Res. 2017;42(10):2755–2768.
   PubMed Web of Science ®Google Scholar
• Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008 Feb;9(2):139–150.
   PubMed Web of Science ®Google Scholar
• Diestel A, Aktas O, Hackel D, et al. Activation of microglial poly(ADP-ribose)-polymerase-1 by cholesterol breakdown products during neuroinflammation: a link between demyelination and neuronal damage. J Exp Med. 2003;198(11):1729–1740.
   PubMed Web of Science ®Google Scholar
• Safaiyan S, Kannaiyan N, Snaidero N, et al. Age-related myelin degradation burdens the clearance function of microglia during aging. Nat Neurosci. 2016;19(8):995–998.
   PubMed Web of Science ®Google Scholar
• Garseth M, White LR, Aasly J. Little change in cerebrospinal fluid amino acids in subtypes of multiple sclerosis compared with acute polyradiculoneuropathy. Neurochem Int. 2001;39(2):111–115.
   PubMed Web of Science ®Google Scholar
• Musgrave T, Tenorio G, Rauw G, et al. Tissue concentration changes of amino acids and biogenic amines in the central nervous system of mice with experimental autoimmune encephalomyelitis (EAE). Neurochem Int. 2011;59(1):28–38.
   PubMed Web of Science ®Google Scholar
• Nogueras L, Gonzalo H, Jové M, et al. Lipid profile of cerebrospinal fluid in multiple sclerosis patients: a potential tool for diagnosis. Sci Rep. 2019 Aug 5;9(1):11313.
   PubMedGoogle Scholar
• Gonzalo H, Brieva L, Tatzber F, et al. Lipidome analysis in multiple sclerosis reveals protein lipoxidative damage as a potential pathogenic mechanism. J Neurochem. 2012;123(4):622‐634.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Huber BR, Zhang J. An update on CSF biomarkers of Parkinson’s disease. In: Mandel S, editor. Neurodegenerative diseases: integrative PPPM approach as the medicine of the future: advances in predictive, preventive, and personalized medicine. Vol. 2. Dordrecht: Springer; 2013. p. 161–184.
   Google Scholar
• Bogdanov M, Matson WR, Wang L, et al. Metabolomic profiling to develop blood biomarkers for Parkinson’s disease. Brain. 2008;131(Pt 2):389‐396.
   PubMedGoogle Scholar
• Carvalho C, Correia SC, Cardoso S, et al. The role of mitochondrial disturbances in Alzheimer, Parkinson and Huntington diseases. Expert Rev Neurother. 2015;15(8):867–884.
   PubMed Web of Science ®Google Scholar
• Vilchez D, Saez I, Dillin A. The role of protein clearance mechanisms in organismal ageing and age-related diseases. Nat Commun. 2014;5(1):5659.
   PubMedGoogle Scholar
• LeWitt PA, Li J, Lu M, et al. Parkinson study group–DATATOP investigators. Metabolomic biomarkers as strong correlates of Parkinson disease progression. Neurology. 2017 Feb 28;88(9):862–869.
   PubMed Web of Science ®Google Scholar
• Palacios N, Gao X, McCullough ML, et al. Caffeine and the risk of Parkinson’s disease in a large cohort of men and women. Mov Disord. 2013;27(10):1276–1282.
   Web of Science ®Google Scholar
• Loeffler DA, LeWitt PA, Juneau PL, et al. Altered guanosine and guanine concentrations in rabbit striatum following increased dopamine turnover. Brain Res Bull. 1998;45(3):297–299.
   PubMed Web of Science ®Google Scholar
• Tyurina YY, Polimova AM, Maciel E, et al. LC/MS analysis of cardiolipins in substantia nigra and plasma of rotenonetreated rats: implication for mitochondrial dysfunction in Parkinson’s disease. Free Radic Res. 2015;49(5):681–691.
   PubMed Web of Science ®Google Scholar
• Fagotti J, Targa ADS, Rodrigues LS, et al. Chronic sleep restriction in the rotenone Parkinson’s disease model in rats reveals peripheral early-phase biomarkers. Sci Rep. 2019 Feb 13;9(1):1898.
   PubMedGoogle Scholar
• Farmer K, Smith CA, Hayley S, et al. Major alterations of phosphatidylcholine and lysophosphotidyl lipids in the substantia nigra using an early stage model of Parkinson’s disease. Int J Mol Sci. 2015;16(8):18865–18877.
   PubMed Web of Science ®Google Scholar
• Morton AJ, Middleton B, Rudiger S, et al. Increased plasma melatonin in presymptomatic Huntington disease sheep (Ovis aries): compensatory neuroprotection in a neurodegenerative disease? J Pineal Res. 2020 Mar; 68(2):e12624.
   PubMed Web of Science ®Google Scholar
• Chiang MC, Chen HM, Lee YH, et al. Dysregulation of C/EBPalpha by mutant Huntingtin causes the urea cycle deficiency in Huntington’s disease. Hum Mol Genet. 2007;16(5):483–498.
   PubMed Web of Science ®Google Scholar
• Chen CM, Lin YS, Wu YR, et al. High protein diet and Huntington’s disease. PLoS One. 2015 May 19;10(5):e0127654.
   PubMed Web of Science ®Google Scholar
• Skene DJ, Middleton B, Fraser CK, et al. Metabolic profiling of presymptomatic Huntington’s disease sheep reveals novel biomarkers. Sci Rep. 2017 Feb 22;7(1):43030.
   PubMedGoogle Scholar
• Gray PA, Burtness HI. Hypoglycemic headache. Endocrinology. 1935;19(5):549–560.
   Google Scholar
• Amery WK. Brain hypoxia: the turning- point in the genesis of the migraine attack? Cephalalgia. 1982;2(2):83–109.
   PubMed Web of Science ®Google Scholar
• Pingitore A, Lima GP, Mastorci F, et al. Exercise and oxidative stress: potential effects of antioxidant dietary strategies in sports. Nutrition. 2015;31(7–8):916–922.
   PubMed Web of Science ®Google Scholar
• Powers SK, Radak Z, Ji LL. Exercise-induced oxidative stress: past, present and future. J Physiol. 2016;594(18):5081–5092.
   PubMed Web of Science ®Google Scholar
• Schoonman GG, Evers DJ, Terwindt GM, et al. The prevalence of premonitory symptoms in migraine: a questionnaire study in 461 patients. Cephalalgia. 2006;26(10):1209–1213.
   PubMed Web of Science ®Google Scholar
• Arngrim N, Schytz HW, Britze J, et al. Migraine induced by hypoxia: an MRI spectroscopy and angiography study. Brain. 2016 Mar;139(Pt 3):723–737.
   PubMedGoogle Scholar
• Trivedi MS, Holger D, Bui AT, et al. Short-term sleep deprivation leads to decreased systemic redox metabolites and altered epigenetic status. PloS One. 2017;12(7):e0181978.
   PubMed Web of Science ®Google Scholar
• Reyngoudt H, Paemeleire K, Descamps B, et al. 31 P-MRS demonstrates a reduction in high-energy phosphates in the occipital lobe of migraine without aura patients. Cephalalgia. 2011;31(12):1243–1253.
   PubMed Web of Science ®Google Scholar
• Welch KM, Levine SR, D’Andrea G, et al. Preliminary observations on brain energy metabolism in migraine studied by in vivo phosphorus 31 NMR spectroscopy. Neurology. 1989;39(4):538–541.
   PubMed Web of Science ®Google Scholar
• Barbiroli B, Montagna P, Cortelli P, et al. Abnormal brain and muscle energy metabolism shown by 31P magnetic resonance spectroscopy in patients affected by migraine with aura. Neurology. 1992 Jun;42(6):1209–1214.
   PubMed Web of Science ®Google Scholar
• Montagna P, Cortelli P, Monari L, et al. 31P-magnetic resonance spectroscopy in migraine without aura. Neurology. 1994 Apr;44(4):666–669.
   PubMed Web of Science ®Google Scholar
• Lodi R, Montagna P, Soriani S, et al. Deficit of brain and skeletal muscle bioenergetics and low brain magnesium in juvenile migraine: an in vivo 31P magnetic resonance spectroscopy interictal study. Pediatr Res. 1997 Dec;42(6):866–871.
   PubMed Web of Science ®Google Scholar
• Lodi R, Iotti S, Cortelli P, et al. Deficient energy metabolism is associated with low free magnesium in the brains of patients with migraine and cluster headache. Brain Res Bull. 2001 Mar 1;54(4):437–441.
   PubMed Web of Science ®Google Scholar
• Schulz UG, Blamire AM, Corkill RG, et al. Association between cortical metabolite levels and clinical manifestations of migrainous aura: an MR-spectroscopy study. Brain. 2007 Dec;130(Pt 12):3102–3110.
   PubMedGoogle Scholar
• Kim JH, Kim S, Suh SI, et al. Interictal metabolic changes in episodic migraine: a voxel-based FDG-PET study. Cephalalgia. 2010 Jan;30(1):53–61.
   PubMed Web of Science ®Google Scholar
• Reyngoudt H, Achten E, Paemeleire K. Magnetic resonance spectroscopy in migraine: what have we learned so far? Cephalalgia. 2012;32(11):845–859.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Kuwabara T, Ohkubo M, et al. Elevation of cerebral lactate detected by localized 1H-magnetic resonance spectroscopy in migraine during the interictal period. Neurology. 1996;47(4):1093–1095.
   PubMed Web of Science ®Google Scholar
• Sándor PS, Dydak U, Schoenen J, et al. MR-spectroscopic imaging during visual stimulation in subgroups of migraine with aura. Cephalalgia. 2005 Jul;25(7):507–518.
   PubMed Web of Science ®Google Scholar
• Prescot A, Becerra L, Pendse G, et al. Excitatory neurotransmitters in brain regions in interictal migraine patients. Mol Pain. 2009;5:34.
   PubMed Web of Science ®Google Scholar
• Reyngoudt H, Paemeleire K, Dierickx A, et al. Does visual cortex lactate increase following photic stimulation in migraine without aura patients? A functional (1)H-MRS study. J Headache Pain. 2011 Jun;12(3):295–302.
   PubMed Web of Science ®Google Scholar
• Mohamed RE, Aboelsafa AA, Al-Malt AM. Interictal alterations of thalamic metabolic concentration ratios in migraine without aura detected by proton magnetic resonance spectroscopy. Egypt J Radio Nucl Med. 2013;44(4):859–870.
   Google Scholar
• Becerra L, Veggeberg R, Prescot A, et al. A ‘complex’ of brain metabolites distinguish altered chemistry in the cingulate cortex of episodic migraine patients. Neuroimage Clin. 2016;11:588–594.
   PubMed Web of Science ®Google Scholar
• Sappey-Marinier D, Calabrese G, Fein G, et al. Effect of photic stimulation on human visual cortex lactate and phosphates using 1H and 31P magnetic resonance spectroscopy. J Cereb Blood Flow Metab. 1992 Jul;12(4):584–592.
   PubMed Web of Science ®Google Scholar
• Gross EC, Lisicki M, Fischer D, et al. The metabolic face of migraine from pathophysiology to treatment. Nat Rev Neurol. 2019 Nov;15(11):627–643.
   PubMed Web of Science ®Google Scholar
• Niemann A, Berger P, Suter U. Pathomechanisms of mutant proteins in Charcot-Marie-Tooth disease. Neuromolecular Med. 2006;8(1–2):217–242.
   PubMed Web of Science ®Google Scholar
• Timmerman V, Strickland AV, Züchner S. Genetics of Charcot-Marie-Tooth (CMT) disease within the frame of the Human Genome Project success. Genes (Basel). 2014;5(1):13–32.
   PubMed Web of Science ®Google Scholar
• Fridman V, Bundy B, Reilly MM, et al. CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis. J Neurol Neurosurg Psychiatry. 2015;86(8):873–878.
   PubMed Web of Science ®Google Scholar
• Klein CJ, Duan X, Shy ME. Inherited neuropathies: clinical overview and update. Muscle Nerve. 2013;48(4):604–622.
   PubMed Web of Science ®Google Scholar
• Saporta AS, Sottile SL, Miller LJ, et al. Charcot–Marie–Tooth disease subtypes and genetic testing strategies. Ann Neurol. 2011;69(1):22–33.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Bruna J, Genazzani AA, et al. Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics. Nat Rev Neurol. 2017 Aug;13(8):492–504.
   PubMed Web of Science ®Google Scholar
• Bais P, Beebe K, Morelli KH, et al. Metabolite profile of a mouse model of Charcot-Marie-Tooth type 2D neuropathy: implications for disease mechanisms and interventions. Biol Open. 2016 Jul 15;5(7):908–920.
   PubMed Web of Science ®Google Scholar
• Callander N, Markovina S, Eickhoff J, et al. Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. Cancer Chemother Pharmacol. 2014;74(4):875–882.
   PubMed Web of Science ®Google Scholar
• Rojas DR, Kuner R, Agarwal N. Metabolomic signature of type 1 diabetes-induced sensory loss and nerve damage in diabetic neuropathy. J Mol Med (Berl). 2019 Jun; 97(6):845–854.
   PubMed Web of Science ®Google Scholar
• Tang HY, Chiu DT, Lin JF, et al. Disturbance of plasma lipid metabolic profile in Guillain-Barre syndrome. Sci Rep. 2017 Aug 15;7(1):8140.
   PubMedGoogle Scholar
• Park SJ, Kim JK, Kim HH, et al. Integrative metabolomics reveals unique metabolic traits in Guillain-Barré Syndrome and its variants. Sci Rep. 2019 Jan 31;9(1):1077.
   PubMedGoogle Scholar
• Capodivento G, Visigalli D, Garnero M, et al. Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies. Sci Rep. 2017;7(1):7831.
   PubMedGoogle Scholar
• Park SJ, Jeong IH, Kong BS, et al. Disease type- and status-specific alteration of CSF metabolome coordinated with clinical parameters in inflammatory demyelinating diseases of CNS. PLoS One. 2016 Nov 17;11(11):e0166277.
   PubMed Web of Science ®Google Scholar
• Chakraborty G, Mekala P, Yahya D, et al. Intraneuronal N‐acetylaspartate supplies acetyl groups for myelin lipid synthesis: evidence for myelin‐associated aspartoacylase. J Neurochem. 2001;78(4):736–745.
   PubMed Web of Science ®Google Scholar
• Karelson G, Ziegler A, Künnecke B, et al. Feeding versus infusion: a novel approach to study the NAA metabolism in rat brain. NMR Biomed. 2003;16(67):413–423.
   PubMedGoogle Scholar
• Moffett JR, Ross B, Arun P, et al. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol. 2007;81(2):89–131.
   PubMed Web of Science ®Google Scholar
• Fujiwara S, Oshika H, Motoki K, et al. Diabetic ketoacidosis associated with Guillain-Barré syndrome with autonomic dysfunction. Int Med. 2000 Jul 10;89(7):1398–1414.
   Google Scholar
• Wang Y, Li G, Yang S, et al. Fasting glucose levels correlate with disease severity of Guillain-Barré syndrome. PloS One. 2015;10(12):e0145075.
   PubMed Web of Science ®Google Scholar
• Ghasemlou N, Jeong SY, Lacroix S, et al. T cells contribute to lysophosphatidylcholine‐induced macrophage activation and demyelination in the CNS. Glia. 2007;55(3):294–302.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Cornblath DR. Chemotherapy-induced peripheral neurotoxicity: facts, needs and future directions. J Peripher Nerv Syst. 2019 Oct;24(Suppl 2):S86–S87.
   PubMedGoogle Scholar
• André N, Braguer D, Brasseur G, et al. Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells. Cancer Res. 2000;60(19):5349–5353.
   PubMed Web of Science ®Google Scholar
• Bernardi P, Krauskopf A, Basso E, et al. The mitochondrial permeability transition from in vitro artifact to disease target. Febs J. 2006;273(10):2077–2099.
   PubMed Web of Science ®Google Scholar
• Flatters SJ, Bennett GJ. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain. 2006;122(3):245–257.
   PubMed Web of Science ®Google Scholar
• Martin LJ, Gertz B, Pan Y, et al. The mitochondrial permeability transition pore in motor neurons: involvement in the pathobiology of ALS mice. Exp Neurol. 2009;218(2):333–346.
   PubMed Web of Science ®Google Scholar
• Xiao W, Boroujerdi A, Bennett GJ, et al. Chemotherapyevoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit. Neuroscience. 2007;144(2):714–720.
   PubMed Web of Science ®Google Scholar
• Nieto FR, Entrena JM, Cendán CM, et al. Tetrodotoxin inhibits the development and expression of neuropathic pain induced by paclitaxel in mice. Pain. 2008;137(3):520–531.
   PubMed Web of Science ®Google Scholar
• Zhang YY, Li G, Che H, et al. Characterization of functional ion channels in human cardiac c-kit+ progenitor cells. Basic Res Cardiol. 2014;109(3):407.
   PubMed Web of Science ®Google Scholar
• Ledeboer A, Jekich BM, Sloane EM, et al. Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. Brain Behav Immun. 2007;21(5):686–698.
   PubMed Web of Science ®Google Scholar
• Dutra RC, Bicca MA, Segat GC, et al. The antinociceptive effects of the tetracyclic triterpene euphol in inflammatory and neuropathic pain models: the potential role of PKCε. Neuroscience. 2015;303:126–137.
   PubMed Web of Science ®Google Scholar
• Li D, Huang ZZ, Ling YZ, et al. Up-regulation of CX3CL1 via nuclear factor-kappab-dependent histone acetylation is involved in paclitaxel-induced peripheral neuropathy. Anesthesiology. 2015;122(5):1142–1151.
   PubMed Web of Science ®Google Scholar
• Wu FZ, Xu WJ, Deng B, et al. Wen-luo-tong decoction attenuates paclitaxel-induced peripheral neuropathy by regulating linoleic acid and glycerophospholipid metabolism pathways. Front Pharmacol. 2018 Aug;28(9):956.
   Google Scholar
• Patwardhan AM, Akopian AN, Ruparel NB, et al. Heat generates oxidized linoleic acid metabolites that activate TRPV1 and produce pain in rodents. J Clin Invest. 2010;120(5):1617–1626.
   PubMed Web of Science ®Google Scholar
• Wang HY, Tsai YJ, Chen SH, et al. Lysophosphatidylcholine causes neuropathic pain via the increase of neuronal nitric oxide synthase in the dorsal root ganglion and cuneate nucleus. Pharmacol. Biochem Behav. 2013;106: 47–56.
   PubMed Web of Science ®Google Scholar
• Sisignano M, Angioni C, Park CK, et al. Targeting CYP2J to reduce paclitaxel-induced peripheral neuropathic pain. Proc Natl Acad Sci USA. 2016;113(5):12544–12549.
   PubMedGoogle Scholar
• Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011;27(1):441–464.
   PubMed Web of Science ®Google Scholar
• Ahn CS, Metallo CM. Mitochondria as biosynthetic factories for cancer proliferation. Cancer Metab. 2015;3(1):1.
   PubMedGoogle Scholar
• Young RM, Ackerman D, Quinn ZL, et al. Dysregulated mTORC1 renders cells critically dependent on desaturated lipids for survival under tumor-like stress. Genes Dev. 2013;27(10):1115–1131.
   PubMed Web of Science ®Google Scholar
• Krishnaiah SY, Wu G, Altman BJ, et al. Clock regulation of metabolites reveals coupling between transcription and metabolism. Cell Metab. 2017 Apr 4;25(4):961–974.e4.
   PubMed Web of Science ®Google Scholar